NASDAQ:CLLS Cellectis H1 2026 Earnings Report $1.51 -0.02 (-1.31%) As of 04:00 PM Eastern ProfileEarnings HistoryForecast Cellectis EPS ResultsActual EPS-$0.22Consensus EPS -$0.26Beat/MissBeat by +$0.04One Year Ago EPSN/ACellectis Revenue ResultsActual Revenue$6.90 millionExpected Revenue$11.05 millionBeat/MissMissed by -$4.15 millionYoY Revenue GrowthN/ACellectis Announcement DetailsQuarterH1 2026Date8/7/2026TimeAfter Market ClosesConference Call DateThursday, August 6, 2026Conference Call Time11:40AM ETUpcoming EarningsCellectis' Q3 2026 earnings is estimated for Friday, November 13, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 3:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (6-K)Press ReleaseInterim ReportEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(6-K)Press ReleaseInterim report Cellectis Earnings HeadlinesCLLS Investors Have Opportunity to Join Cellectis S.A. Fraud Investigation with SBS LawSeptember 19 at 7:31 PM | businesswire.comSecurities Fraud Investigation Into Cellectis S.A. (CLLS) Announced - Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud ...September 17, 2026 | tmcnet.comBezos… DOOMEDA single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X combined - aimed at the $25 trillion AI industry. James Altucher says the plan could cut Amazon out of the AI race and disrupt Blue Origin, with a key deadline landing September 25.September 21 at 1:00 AM | Paradigm Press (Ad)CLLS INVESTOR ALERT: Investigation of Cellectis S.A. Announced by Holzer & Holzer, LLCSeptember 17, 2026 | globenewswire.comCellectis (CLLS) Exits Two CAR-T Programs. Can Gene Editing Justify the Clinical Reset?September 17, 2026 | insidermonkey.comWells Fargo & Company Lowers Cellectis (NASDAQ:CLLS) Price Target to $3.00September 17, 2026 | americanbankingnews.comSee More Cellectis Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Cellectis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cellectis and other key companies, straight to your email. Email Address About CellectisCellectis (NASDAQ:CLLS) (NASDAQ: CLLS) is a clinical-stage biotechnology company focused on developing gene-edited, allogeneic T-cell therapies for cancer. The company uses its gene-editing technologies, including TALEN-based technology, to modify immune cells so they can be manufactured in advance and potentially administered to multiple patients rather than produced individually. Cellectis’ product candidates are designed primarily as chimeric antigen receptor T-cell (CAR-T) therapies for hematologic malignancies and other serious diseases. Its pipeline has included UCART programs targeting blood cancers, with research focused on improving the persistence, safety and activity of off-the-shelf engineered immune-cell products. The company advances its programs through internal research, clinical development and strategic collaborations. Founded in 1999, Cellectis has operations and research activities in France and the United States, serving the global biopharmaceutical and oncology markets. The company has also pursued collaborations with larger pharmaceutical companies, including AstraZeneca, to support the development of gene-edited cell therapies. Cellectis is headquartered in Paris, France, and is led by co-founder André Choulika, who has served as chief executive officer.View Cellectis ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 5 Dividend Stocks That Combine Income, Earnings Growth, and Wall Street SupportCoach’s Momentum Powers Tapestry Despite the Stock’s Sharp Pullback3 Retail Stocks Getting Crushed and the Long-Dated Options Trade on Each One3 Surging Stocks That Don’t Need the AI Boom to Keep WinningJ.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. Housing3 Software Stocks Rebounding as AI Fears Give Way to Growth Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
